Vor Biopharma (VOR) Cash & Equivalents (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Cash & Equivalents data on file, last reported at $169.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 239.43% year-over-year to $169.9 million in Q1 2026; TTM through Mar 2026 was $169.9 million, a 239.43% increase from a year earlier, with the FY2025 full-year figure at $396.5 million, up 383.82% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $169.9 million, down from $396.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for VOR reached as high as $396.5 million in Q4 2025 and fell as low as $31.4 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $96.8 million across 5 years, with a median of $60.8 million in 2022.
• Across the five-year window, Cash & Equivalents sank 65.71% in 2022 and surged 383.82% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $57.7 million in 2022, then slumped by 45.66% to $31.4 million in 2023, then surged by 161.32% to $81.9 million in 2024, then jumped by 383.82% to $396.5 million in 2025, then sank by 57.16% to $169.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $169.9 million in Q1 2026, $396.5 million in Q4 2025, and $160.5 million in Q3 2025.